CSL Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

CSL wird ein jährliches Gewinn- und Umsatzwachstum von 14.7% bzw. 7.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.8% betragen.

Wichtige Informationen

14.7%

Wachstumsrate der Gewinne

14.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	31.2%
Wachstumsrate der Einnahmen	7.3%
Zukünftige Eigenkapitalrendite	18.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	21 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DB:CSJ - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2026	17,076	3,768	3,608	4,476	14
6/30/2025	15,935	3,250	2,907	3,795	15
6/30/2024	14,719	2,699	2,205	3,124	15
12/31/2023	14,179	2,472	1,158	2,690	N/A
9/30/2023	13,745	2,333	1,034	2,646	N/A
6/30/2023	13,310	2,194	909	2,601	N/A
3/31/2023	12,508	2,156	766	2,391	N/A
12/31/2022	11,705	2,118	622	2,182	N/A
9/30/2022	11,133	2,186	1,001	2,406	N/A
6/30/2022	10,562	2,255	1,381	2,629	N/A
3/31/2022	10,587	2,290	1,251	2,679	N/A
12/31/2021	10,612	2,325	1,121	2,728	N/A
9/30/2021	10,461	2,350	1,538	3,175	N/A
6/30/2021	10,310	2,375	1,955	3,622	N/A
3/31/2021	10,145	2,520	2,127	3,597	N/A
12/31/2020	9,980	2,665	2,299	3,571	N/A
9/30/2020	9,565	2,384	1,710	3,030	N/A
6/30/2020	9,151	2,103	1,121	2,488	N/A
3/31/2020	9,048	2,054	1,009	2,418	N/A
12/31/2019	8,944	2,006	897	2,347	N/A
9/30/2019	8,742	1,962	628	1,996	N/A
6/30/2019	8,539	1,919	360	1,644	N/A
3/31/2019	8,406	1,861	426	1,621	N/A
12/31/2018	8,274	1,803	492	1,597	N/A
9/30/2018	8,094	1,766	701	1,750	N/A
6/30/2018	7,915	1,729	910	1,902	N/A
3/31/2018	7,666	1,674	691	1,662	N/A
12/31/2017	7,417	1,618	473	1,422	N/A
9/30/2017	7,182	1,478	N/A	1,335	N/A
6/30/2017	6,947	1,337	N/A	1,247	N/A
3/31/2017	6,802	1,333	N/A	1,192	N/A
12/31/2016	6,656	1,329	N/A	1,138	N/A
9/30/2016	6,386	1,286	N/A	1,158	N/A
6/30/2016	6,115	1,242	N/A	1,179	N/A
3/31/2016	5,983	1,324	N/A	1,296	N/A
12/31/2015	5,850	1,406	N/A	1,413	N/A
9/30/2015	5,654	1,392	N/A	1,388	N/A
6/30/2015	5,459	1,379	N/A	1,364	N/A
3/31/2015	5,482	1,366	N/A	1,434	N/A
12/31/2014	5,505	1,354	N/A	1,504	N/A
9/30/2014	5,420	1,330	N/A	1,432	N/A
6/30/2014	5,335	1,307	N/A	1,361	N/A
3/31/2014	5,189	1,270	N/A	1,257	N/A
12/31/2013	5,042	1,233	N/A	1,154	N/A
9/30/2013	4,996	1,222	N/A	1,233	N/A
6/30/2013	4,950	1,211	N/A	1,312	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CSJDas prognostizierte Gewinnwachstum (14.7% pro Jahr) liegt über der Sparquote (0.7%).

Ertrag vs. Markt: CSJDie Erträge des Unternehmens (14.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt German (18.6% pro Jahr).

Hohe Wachstumserträge: CSJDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: CSJDie Einnahmen des Unternehmens (7.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (5.1% pro Jahr).

Hohe Wachstumseinnahmen: CSJDie Einnahmen des Unternehmens (7.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CSJDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.8%).

CSL Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited Provides Financial Guidance for Fiscal 2022

Recent updates

Now 20% undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Now 22% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold €3.3m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings released: EPS: US$4.55 (vs US$4.81 in FY 2022)

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of US$1.07 per share at 1.1% yield

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Now 21% undervalued after recent price drop

Independent Non-Executive Director recently bought €174k worth of stock

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Non-Independent Non-Executive Director recently sold €4.3m worth of stock

Upcoming dividend of US$1.18 per share

Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021)

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Now 23% undervalued

Upcoming dividend of US$1.04 per share

Now 22% undervalued after recent price drop

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Vifor Says Regularly in Talks with Other Market Participants After Reports

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

MD, CEO & Executive Director recently sold €2.9m worth of stock

MD, CEO & Executive Director recently sold €3.0m worth of stock

High number of new directors

Upcoming dividend of US$1.18 per share

Full year 2021 earnings released: EPS US$5.22 (vs US$4.63 in FY 2020)

CSL Limited Provides Financial Guidance for Fiscal 2022

Independent Non-Executive Director Shah Hussain has left the company

Seqirus Announces Health Canada Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older

New 90-day low: €164

Independent Non-Executive Chairman recently bought €53k worth of stock

First half 2021 earnings released: EPS US$3.98 (vs US$2.75 in 1H 2020)

Revenue beats expectations

CSL Limited to Report First Half, 2021 Results on Feb 18, 2021

Independent Non-Executive Director has left the company

CSL Limited Announces Resignation of Pascal Soriot from the Position of Non-Executive Director, Effective 1 February 2021

New 90-day low: €172

New 90-day high: €189

CSL Limited Announces Management Changes